FIELD: organic chemistry.
SUBSTANCE: present invention relates to the field of organic chemistry, in particular to the use of an ester of 4-aminofuro [2,3-d] pyrimidine-5-carboxylic acid of formulas 1.1, 1.2 or 1.3
to inhibit hepatitis B virus.
EFFECT: new use of 4-aminofuro [2,3-d] pyrimidine-5-carboxylic acid esters as inhibitors of hepatitis B virus.
1 cl, 1 tbl, 35 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HEPATITIS B VIRUS INHIBITOR (HBV) | 2019 |
|
RU2736975C1 |
| HEPATITIS B VIRUS (HBV) INHIBITOR | 2019 |
|
RU2726456C1 |
| HEPATITIS B VIRUS (HBV) INHIBITOR, WHICH IS A DERIVATIVE OF N-{3-[6-(DIALKYLAMINO)PYRIDAZINE-3-YL]PHENYL}ARYL SULPHONAMIDE DERIVATIVES AND DERIVATIVES OF N-{4-[6-(DIALKYLAMINO)PYRIDAZINE-3-YL]PHENYL}ARYL SULPHONAMIDE | 2019 |
|
RU2738848C1 |
| MACROHETEROCYCLIC NUCLEOSIDE DERIVATIVES AND ANALOGUES THEREOF, PRODUCTION AND USE | 2017 |
|
RU2731385C1 |
| PARTIAL AGONIST OF DOPAMIN D2/D3 RECEPTORS - 4-{2-[4-(2,3-DICHLOROPHENIL)-PIPERAZIN-1-YL]-ETHYL}-PYPERIDIN-1-CARBONIC ACID METHILAMIDE, METHODS (OPTIONS) OF ITS OBTAINMENT AND APPLICATION | 2018 |
|
RU2677268C1 |
| SUBSTITUTED PYRIMIDINES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, OR N-OXIDES, METHODS OF THEIR SYNTHESIS AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 1992 |
|
RU2113437C1 |
| PAN-GENOMIC INHIBITORS OF THE HEPATITIS C VIRUS PROTEIN NS5A, PHARMACEUTICAL COMPOSITIONS, INTERMEDIATES FOR THE SYNTHESIS OF INHIBITORS, AND METHODS FOR THEIR PREPARATION AND USE | 2016 |
|
RU2669919C1 |
| NEW PYRROLO[3,2-d]PYRIMIDIN-4-ONE DERIVATIVES AND USING THEM IN THERAPY | 2005 |
|
RU2577858C2 |
| FURO[3,2-B]- AND THIENO[3,2-B]PYRIDINE DERIVATIVES AS TBK1 AND IKKε INHIBITORS | 2013 |
|
RU2622034C2 |
| 3-AMINOCYCLOPENTANCARBOXAMIDE DERIVATIVES | 2013 |
|
RU2641913C2 |
